H
Huiqin Chen
Researcher at University of Texas MD Anderson Cancer Center
Publications - 69
Citations - 2668
Huiqin Chen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 58 publications receiving 2186 citations. Previous affiliations of Huiqin Chen include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo,Kirsten Timms,Shuying Liu,Huiqin Chen,Jennifer K. Litton,Jennifer Potter,Jerry S. Lanchbury,Katherine Stemke-Hale,Bryan T. Hennessy,Banu Arun,Gabriel N. Hortobagyi,Kim Anh Do,Gordon B. Mills,Funda Meric-Bernstam +13 more
TL;DR: Investigating the incidence of germline and somatic BRCA1/2 mutations in unselected patients with triple-negative breast cancer and determining the prognostic significance of carrying a mutation found a 19.5% incidence.
Journal ArticleDOI
Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf,Yun Wu,Maurizio Scaltriti,Funda Meric-Bernstam,Kelly K. Hunt,Shaheenah Dawood,Francisco J. Esteva,Aman U. Buzdar,Huiqin Chen,Sameena Eksambi,Gabriel N. Hortobagyi,José Baselga,Ana M. Gonzalez-Angulo +12 more
TL;DR: High pCR rates are achieved in patients with HER2-positive breast cancer treated with neoadjuvant trastuzumab in combination with anthracyclines and taxanes, and novel adjuvant therapy strategies need to be studied in this population.
Journal ArticleDOI
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam,Argun Akcakanat,Huiqin Chen,Kim Anh Do,Takafumi Sangai,Farrell Adkins,Ana M. Gonzalez-Angulo,Asif Rashid,Katherine Crosby,Mei Dong,Alexandria T. Phan,Robert A. Wolff,Sanjay Gupta,Gordon B. Mills,James C. Yao +14 more
TL;DR: Rapamycin-mediated Akt activation is greater in RS cells, with a similar observation in patients with clinical responses on exploratory biomarker analysis; thus feedback loop activation of Akt is not a marker of resistance but rather may function as an indicator of rapamycin activity.
Journal ArticleDOI
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Takafumi Sangai,Argun Akcakanat,Huiqin Chen,Emily Tarco,Yun Wu,Kim Anh Do,Todd W. Miller,Carlos L. Arteaga,Gordon B. Mills,Ana M. Gonzalez-Angulo,Funda Meric-Bernstam +10 more
TL;DR: In vitro, MK-2206 showed a synergistic interaction with paclitaxel in MK- 2206–sensitive cell lines, and this combination had significantly greater antitumor efficacy than either agent alone in vivo.
Journal ArticleDOI
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/ PTEN mutation
Yan Xing,Nan Lin,Matthew A. Maurer,Matthew A. Maurer,Huiqin Chen,Armeen Mahvash,Aysegul A. Sahin,Argun Akcakanat,Yisheng Li,Vandana G. Abramson,Jennifer K. Litton,Mariana Chavez-MacGregor,Vicente Valero,Sarina Anne Piha-Paul,David S. Hong,Kim Anh Do,Emily Tarco,Dianna Riall,Agda Karina Eterovic,Gerburg M. Wulf,Lewis C. Cantley,Gordon B. Mills,L. Austin Doyle,Eric P. Winer,Gabriel N. Hortobagyi,Ana M. Gonzalez-Angulo,Funda Meric-Bernstam +26 more
TL;DR: MK-2206 monotherapy had limited clinical activity in advanced breast cancer patients selected for PIK3CA/AKT1 or PTEN mutations orPTEN loss, and may be due to inadequate target inhibition at tolerable doses in heavily pre-treated patients with pathway activation.